Claudia Panzer, MD
Endocrinology, Diabetes & Metabolism · Denver, CONPI 1538122007
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,735 of the $3,336 with a category attached, or 82.0%. It is spread thinly across 23 manufacturers, the largest accounting for just 16.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $899 and has fallen 55.0% since, to $405 in 2025.
Across 95 payments — averaging $35.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amneal Pharmaceuticals LLC$549
- Medtronic$494
- Senseonics, Incorporated$400
- AstraZeneca$308
- Lilly USA, LLC$262
- Radius Health, Inc.$246
- plus $1K from 17 others
What the payments were for
- Speaking & faculty fees$40012%
- Food & beverage$2,73582%
- Education$1244%
- Gifts$772%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amneal Pharmaceuticals LLC | 34 | $549 |
| Medtronic | 7 | $494 |
| Senseonics, Incorporated | 1 | $400 |
| AstraZeneca(2 entities) | 5 | $308 |
| Lilly USA, LLC | 9 | $262 |
| Radius Health, Inc. | 2 | $246 |
| Mannkind Corporation | 10 | $223 |
| Amgen | 2 | $210 |
| Bayer | 3 | $133 |
| Vertical Pharmaceuticals, LLC | 6 | $129 |
| Novo Nordisk | 1 | $113 |
| Currax Pharmaceuticals LLC | 3 | $75 |
| AbbVie | 2 | $27 |
| Neurocrine Biosciences, Inc. | 1 | $25 |
| Amarin Pharma, Inc. | 1 | $23 |
| Ascend Therapeutics US, LLC | 1 | $18 |
| IBSA Pharma Inc. | 1 | $17 |
| Cequr Corporation | 1 | $16 |
| Antares Pharma, Inc. | 1 | $16 |
| Tandem Diabetes Care, Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Insulet Corporation | 1 | $13 |
| Dexcom, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,336 in reported general payments places this provider in the 65th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.
See all endocrinology, diabetes & metabolism providers in Colorado →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 173 | $264,858 |
| OzempicSemaglutide | 119 | $232,532 |
| FarxigaDapagliflozin Propanediol | 66 | $78,469 |
| JardianceEmpagliflozin | 45 | $66,047 |
| TymlosAbaloparatide | 20 | $50,965 |
| RybelsusSemaglutide | 22 | $34,057 |
| Tresiba Flextouch U-200Insulin Degludec | 28 | $21,674 |
| SynthroidLevothyroxine Sodium | 128 | $12,084 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $8,254 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $4,637 |
| Novolog FlexpenInsulin Aspart | 12 | $4,272 |
| Estradiol | 19 | $4,033 |
| UnithroidLevothyroxine Sodium | 49 | $3,964 |
| Testosterone | 19 | $2,848 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 13 | $2,139 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $113 | $266,589141 claims |
| Lilly USA, LLCMounjaro | $262 | $264,858173 claims |
| AstraZenecaFarxiga | $308 | $78,46966 claims |
| Radius Health, Inc.Tymlos | $246 | $50,96520 claims |
| AbbVieSynthroid | $27 | $12,084128 claims |
| Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium | $549 | $5,787245 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.
Other endocrinology, diabetes & metabolism in Denver
- Daniel BessesenDenver$34K
- Michael LoughnerDenver$32K
- Leonard ZemelDenver$19K
- Alex GoldsmithDenver$12K
- Daniel CitronDenver$8K
- Sarah BullDenver$4K
- Leslie GamacheDenver$4K
- Sheila MaierDenver$2K
- Karin HickeyDenver$2K
- Gregory LundDenver$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.